Intensity Therapeutics Reports Positive Phase 2 Data for INT230-6 in TNBC, Resumes Sarcoma Trial Enrollment

summarizeSummary

Intensity Therapeutics reported Q1 2026 financial results and significant clinical updates, including positive preliminary Phase 2 data for INT230-6 in TNBC and plans to resume enrollment in its Phase 3 sarcoma study.

check_boxKey Events

• Positive Phase 2 TNBC Data

  Preliminary INVINCIBLE-4 study results showed 71.4% pathological complete response (pCR) in the INT230-6 + standard of care arm compared to 33% in the standard of care alone arm for triple-negative breast cancer patients, with fewer severe adverse events.

• Sarcoma Trial Resumption

  The company plans to resume enrollment in its INVINCIBLE-3 Phase 3 study for soft tissue sarcoma in a limited number of U.S. sites by Q3 2026, after a pause due to funding constraints.

• Q1 2026 Financials

  Intensity Therapeutics reported a net loss of $2.4 million for the first quarter of 2026, an improvement from $3.3 million in Q1 2025, and held $10.2 million in cash and cash equivalents as of March 31, 2026.

• Funding Strategy

  The company continues to rely on its $60 million At-The-Market (ATM) facility, established in March 2026, to support ongoing operations and clinical trials, as it seeks additional funding.

auto_awesomeAnalysis

This 8-K provides crucial operational updates alongside its Q1 2026 financial results, which were also reported in a 10-Q today. The most significant new information is the positive preliminary Phase 2 data from the INVINCIBLE-4 study in triple-negative breast cancer (TNBC), showing a higher pathological complete response (pCR) rate (71.4% vs. 33%) and fewer adverse events with INT230-6 plus standard of care. The company also announced plans to resume enrollment in its INVINCIBLE-3 sarcoma study, which had been paused due to funding constraints. While the company reiterates its low cash position and reliance on its $60 million ATM facility (as noted in the concurrent 10-Q and prior filings), these clinical advancements provide a much-needed positive catalyst and demonstrate progress in its pipeline, potentially extending its operational runway and attracting further investment.